Clinical Trial Update: Phase 2 Study of GSK1363089 (Formerly XL880) in Adults With Squamous Cell Cancer of the Head and Neck [Phase 2]

View source ↗

Summary

Phase 2 trial of GSK1363089 (formerly XL880) in adults with head and neck squamous cell carcinoma has completed enrollment and posted results in October 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• GSK1363089 (XL880) (GSK1363089)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Neoplasms, Head and Neck | Phase 2 | Status: COMPLETED | Results posted: 2017-10-16